Recap - The congrats this week went to PropThink contributor Ivan Deryugin for his early December suggestion to buy BDSI ahead of a crucial phase 3 readout. The position … Continue Reading
Read nowInsights - AcelRx (ACRX) announced on Monday a partnership with Grunenthal GmbH for the commercialization of Zalviso, the company’s patient-controlled analgesia product, in Europe and Australia. On Thursday, AcelRx entered into … Continue Reading
Read nowInsights - Last week we introduced a new look for PropThink.com and launched a more affordable option for PropThink readers interested in exploring our Premium content. Not to worry, we’ll still … Continue Reading
Read nowResearch - In the biotechnology sector, innovation can come in one of a few forms, including novel drugs or novel ways to deliver existing drugs. BioDelivery Sciences … Continue Reading
PremiumRecap - Darapladib failed two mid-stage studies in 2008, yet GlaxoSmithKline (GSK) moved the cardiovascular drug into Phase III trials nonetheless. While most investors consider the large … Continue Reading
Read nowLong Ideas - BioDelivery Sciences (BDSI) on Monday entered into a $20 million senior secured loan with MidCap Financial and issued to the group a warrant to purchase … Continue Reading
Read nowLong Ideas - Endo Health Solutions’ (ENDP) new CEO is executing on his strategy, as expected, and most of the Street likes what it sees. Endo announced on … Continue Reading
Read now
